Sana Biotechnology
Sana Biotechnology raises $700M IPO at $4.2B valuation
Quick Facts
Sana Biotechnology: IPO Funding Round
Sana Biotechnology has successfully raised $700M in IPO funding, reaching a valuation of $4.2B.
Company Overview
Cell and gene therapy platform
Funding Details
The IPO round was led by Flagship Pioneering, with participation from ARCH Venture Partners, F-Prime Capital, Baillie Gifford.
Company Information
- Headquarters: 188 East Blaine Street, Seattle, WA 98102
- Founded: 2018
- Employees: 400+
- Category: Biotech
Investment
Sana Biotechnology plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Flagship Pioneering: Verified investor in IPO
- ARCH Venture Partners: Verified investor in IPO
- F-Prime Capital: Verified investor in IPO
- Baillie Gifford: Verified investor in IPO
Key Investors
About the Author
Related Company Reports
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...